Loading...

Kathryn Phillips, PhD

Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Address3333 Calif. St,Laurel Heights
San Francisco CA 94118
Phone415-502-8271
ORCID ORCID Icon0000-0003-0822-4968 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFPost-doctoral fellowship
    Kennedy School of Government Harvard UniversityMC-MPA
    University of Texas at AustinBA
    Collapse Awards and Honors
    UC Berkeley1987  - 1988UC Berkeley Graduate Fellowship
    Am J Prev Med1999  - 1999Commendation for outstanding journal reviews
    Univ of CT2003  - 200350 Most Cited HIV Behavioral Researchers in Past Decade
    Research Triangle Institute2010  - 2010Most cited article award
    Bellagio Center Italy2016Rockefeller Foundation Residency
    UCSF2019Dean's Award For Outstanding Teaching
    University of British Columbia2018Honorary Lectureship
    U of Maryland2017Honorary Lectureship

    Collapse Overview 
    Collapse Overview
    Kathryn A. Phillips, PhD, a health services researcher and health economist and leader in the application of new technologies to improve healthcare, is the founding director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy at the University of California, San Francisco (UCSF). She is also a professor of health economics and health services research in the Department of Clinical Pharmacy at UCSF, with additional appointments in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center

    Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is personalized (or precision) medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).

    Kathryn has published ~150 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs and has had continuous funding from the US. National Institutes of Health as a principal investigator for 25 years. She currently serves on the editorial boards of the journal Health Affairs (rated as the top policy journal), Value in Health (a leading outcomes research journal), and all of the leading journals on personalized medicine. Kathryn has served on national and international scientific advisory committees and workshops including work Board of Directors for GenomeCanada, National Academy of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to various international and industry organizations, including more than 35 biotechnology companies and venture capital firms. She was recently awarded a Rockefeller Foundation global and worked with thethe Patient-Centered Outcomes Research Institute (PCORI) - the largest funder of comparative effectiveness research in the world - developing a research agenda on personalized/precision medicine.

    Collapse Research 
    Collapse Research Activities and Funding
    Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
    NIH/NCI R01CA221870Jul 1, 2018 - Jun 30, 2021
    Role: Principal Investigator
    Risk-Benefit Trade-Offs for Whole Genome Sequencing
    NIH/NHGRI R01HG007063Feb 15, 2013 - Jul 31, 2016
    Role: Principal Investigator
    Personalized Medicine for Colorectal and Breast Cancer
    NIH/NCI P01CA130818Sep 16, 2008 - Aug 31, 2013
    Role: Principal Investigator
    Screening for Colorectal Cancer: An Integrated Approach
    NIH/NCI R01CA101849Apr 28, 2004 - Mar 31, 2009
    Role: Principal Investigator
    USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT
    NIH/NCI R01CA081130Feb 1, 2000 - Jan 31, 2003
    Role: Principal Investigator
    UTILIZATION AND COST EFFECTIVENESS OF NEW HIV TESTS
    NIH/NIAID R01AI043744Jul 1, 1999 - Jun 30, 2002
    Role: Principal Investigator
    EFFECTIVENESS AND COST-EFFECTIVENESS OF HIV TESTING
    NIH/NIAID R29AI034864Dec 1, 1993 - Nov 30, 1999
    Role: Principal Investigator
    GOVERNMENT INTERVENTION AND UTILIZATION OF HIV SCREENING
    AHRQ R03HS006629Sep 1, 1990 - Aug 31, 1991
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News
    Collapse Featured Presentations
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. J Natl Compr Canc Netw. 2020 Jul; 18(7):866-872. Douglas MP, Gray SW, Phillips KA. PMID: 32634780.
      View in: PubMed   Mentions:    Fields:    
    2. Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy. Value Health. 2020 May; 23(5):527-528. Phillips KA. PMID: 32389216.
      View in: PubMed   Mentions:    Fields:    
    3. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020 May; 23(5):540-550. Deverka PA, Douglas MP, Phillips KA. PMID: 32389218.
      View in: PubMed   Mentions:    Fields:    
    4. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value Health. 2020 May; 23(5):566-573. Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, Ijzerman M. PMID: 32389221.
      View in: PubMed   Mentions:    Fields:    
    5. Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value Health. 2020 May; 23(5):559-565. Mackay ZP, Dukhovny D, Phillips KA, Beggs AH, Green RC, Parad RB, Christensen KD. PMID: 32389220.
      View in: PubMed   Mentions:    Fields:    
    6. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 May; 23(5):551-558. Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. PMID: 32389219.
      View in: PubMed   Mentions: 1     Fields:    
    7. Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits? Per Med. 2019 09; 16(5):365-367. Phillips KA, Marshall DA, Kurian AW. PMID: 31552799.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2020 02; 22(2):283-291. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. PMID: 31501586.
      View in: PubMed   Mentions: 2     Fields:    
    9. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019 06 25; 321(24):2403-2404. Phillips KA, Trosman JR, Douglas MP. PMID: 31145414.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. J Am Coll Clin Pharm. 2019 Jun; 2(3):214-221. Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. PMID: 32391517.
      View in: PubMed   Mentions:
    11. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. J Precis Med. 2018 Oct; 4. Phillips KA, Douglas MP. PMID: 32149190.
      View in: PubMed   Mentions:
    12. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value Health. 2018 09; 21(9):1031-1032. Phillips KA. PMID: 30224105.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value Health. 2018 09; 21(9):1054-1061. Christensen KD, Phillips KA, Green RC, Dukhovny D. PMID: 30224109.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value Health. 2018 09; 21(9):1033-1042. Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. PMID: 30224106.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018 09; 21(9):1062-1068. Trosman JR, Weldon CB, Gradishar WJ, Benson AB, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. PMID: 30224110.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2019 01; 21(1):152-160. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. PMID: 29997388.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018 06 19; 319(23):2379-2380. Phillips KA. PMID: 29710095.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 05; 37(5):710-716. Phillips KA, Deverka PA, Hooker GW, Douglas MP. PMID: 29733704.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    19. Precision Medicine: From Science To Value. Health Aff (Millwood). 2018 05; 37(5):694-701. Ginsburg GS, Phillips KA. PMID: 29733705.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansPHPublic Health
    20. Insurance coverage for genomic tests. Science. 2018 Apr 20; 360(6386):278-279. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. PMID: 29674586.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. PMID: 29565423.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 01; 20(1):165. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. PMID: 29261179.
      View in: PubMed   Mentions:    Fields:    
    23. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. PMID: 29065945.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 07 12; 35(7):614-617. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. PMID: 28700544.
      View in: PubMed   Mentions: 13     Fields:    
    25. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. PMID: 28993792.
      View in: PubMed   Mentions: 1     Fields:    
    26. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 10; 19(10):1081-1091. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. PMID: 28406488.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    27. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. PMID: 28188191.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    28. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46. Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. PMID: 28212967.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53. Phillips KA, Douglas MP, Trosman JR, Marshall DA. PMID: 28212968.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017 01; 20(1):30-31. Phillips KA. PMID: 28212965.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. PMID: 27657682.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. PMID: 27253734.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Aff (Millwood). 2016 Apr; 35(4):647-53. Phillips KA, Schleifer D, Hagelskamp C. PMID: 27044965.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. PMID: 26348951.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. PMID: 25996638.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. PMID: 25835195.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8. Trosman JR, Weldon CB, Kelley RK, Phillips KA. PMID: 25736008.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    38. Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception. 2015 May; 91(5):373-9. Foster DG, Biggs MA, Phillips KA, Grindlay K, Grossman D. PMID: 25732570.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making. 2015 08 01; 35(6):734-744. Knight SJ, Mohamed AF, Marshall DA, Ladabaum U, Phillips KA, Walsh JM. PMID: 25589525.
      View in: PubMed   Mentions: 1     Fields:    
    40. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care. 2015; 23(3):373-9. Phillips KA, Pletcher MJ, Ladabaum U. PMID: 25669213.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    41. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22. Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips KA. PMID: 25620993.
      View in: PubMed   Mentions: 3     Fields:    
    42. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. PMID: 25006153.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    43. Prostatitis, steatitis, and diarrhea in a dog following presumptive flea-borne transmission of Bartonella henselae. J Clin Microbiol. 2014 Sep; 52(9):3447-52. Balakrishnan N, Pritchard J, Ericson M, Grindem C, Phillips K, Jennings S, Mathews K, Tran H, Birkenheuer AJ, Breitschwerdt EB. PMID: 24920774.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    44. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. PMID: 24232413.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    45. Economic Perspectives on Personalized Health Care and Prevention. Forum Health Econ Policy. 2013 Sep 01; 16(2):S23-S52. Phillips KA, Sakowski JA, Liang SY, Ponce NA. PMID: 31419875.
      View in: PubMed   Mentions:    Fields:    
    46. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract. 2012 May; 8(3 Suppl):e24s-30s. Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. PMID: 22942831.
      View in: PubMed   Mentions: 6     Fields:    
    47. Differences in US healthcare coverage policies in BRCA testing and potential implications. Per Med. 2012 Jan; 9(1):5-8. Beattie MS, Wang G, Phillips KA. PMID: 29783285.
      View in: PubMed   Mentions:    Fields:    
    48. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011 Dec; 13(12):1045-50. Wang G, Beattie MS, Ponce NA, Phillips KA. PMID: 21844812.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    49. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60. Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. PMID: 21637102.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care. 2011 Jun; 49(6):e1-8. Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS. PMID: 21422962.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract. 2011 May; 7(3 Suppl):18s-24s. Trosman JR, Van Bebber SL, Phillips KA. PMID: 21886515.
      View in: PubMed   Mentions: 12     Fields:    
    52. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s. Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. PMID: 21886507.
      View in: PubMed   Mentions: 5     Fields:    
    53. Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care. 2011 May; 17 Suppl 5 Developing:SP53-60. Trosman JR, Van Bebber SL, Phillips KA. PMID: 21711078.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. How does cost matter in health-care discrete-choice experiments? Health Econ. 2011 Mar; 20(3):323-30. Johnson FR, Mohamed AF, Ozdemir S, Marshall DA, Phillips KA. PMID: 20217834.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    55. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. PMID: 21233242.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    56. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract. 2010 Sep; 6(5):238-42. Trosman JR, Van Bebber SL, Phillips KA. PMID: 21197187.
      View in: PubMed   Mentions: 15     Fields:    
    57. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med. 2010 Jul; 7(4):427-439. Van Bebber SL, Trosman JR, Liang SY, Wang G, Marshall DA, Knight S, Phillips KA. PMID: 21857867.
      View in: PubMed   Mentions: 5     Fields:    
    58. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ. 2009 Dec; 18(12):1420-39. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van Bebber S, Phillips KA. PMID: 19191268.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    59. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74. Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. PMID: 19753618.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    60. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med. 2009 Mar; 6(2):193-215. Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips KA. PMID: 20668661.
      View in: PubMed   Mentions: 9     Fields:    
    61. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther. 2008 Jun; 10(3):260-6. Phillips KA, Liang SY, Van Bebber S. PMID: 18535933.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    62. Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis. 2007 Oct; 4(4):A90. Haas JS, Fitzmaurice G, Brawarsky P, Liang SY, Hiatt RA, Klabunde CN, Brown ML, Phillips KA. PMID: 17875265.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    63. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007 Sep-Oct; 10(5):415-30. Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Kulin NA. PMID: 17888107.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansPHPublic Health
    64. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007 Sep; 2(3):177-85. Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW. PMID: 18690965.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    65. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Per Med. 2007 Aug; 4(3):341-350. Van Bebber SL, Liang SY, Phillips KA, Marshall D, Walsh J, Kulin N. PMID: 29788665.
      View in: PubMed   Mentions:    Fields:    
    66. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007 Feb; 45(2):160-7. Phillips KA, Liang SY, Ladabaum U, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. PMID: 17224779.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    67. Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception. 2007 Jan; 75(1):45-51. Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. PMID: 17161124.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Per Med. 2006 Nov; 3(4):411-414. Phillips KA, Van Bebber SL, Issa AM. PMID: 29788589.
      View in: PubMed   Mentions:    Fields:    
    69. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Per Med. 2006 Nov; 3(4):415-419. Van Bebber SL, Keegan HL, Phillips KA, Issa AM. PMID: 29788595.
      View in: PubMed   Mentions:    Fields:    
    70. Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments. Per Med. 2006 Nov; 3(4):421-427. Issa AM, Todd Weiss L, Tufail W, Phillips KA, Van Bebber SL. PMID: 29788596.
      View in: PubMed   Mentions:    Fields:    
    71. Rates and predictors of colorectal cancer screening. Prev Chronic Dis. 2006 Oct; 3(4):A117. Liang SY, Phillips KA, Nagamine M, Ladabaum U, Haas JS. PMID: 16978492.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansPHPublic Health
    72. Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1260-9. Keenan PS, Neumann PJ, Phillips KA. PMID: 16966721.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    73. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1271-80. Phillips KA. PMID: 16966723.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    74. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis. 2006 Jul; 3(3):A75. Phillips KA, Van Bebber S, Marshall D, Walsh J, Thabane L. PMID: 16776876.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    75. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev. 2006 Jun; 63(3):301-26. Phillips KA, Van Bebber SL. PMID: 16651395.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    76. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006 Jun; 5(6):463-9. Phillips KA, Van Bebber S, Issa AM. PMID: 16718275.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    77. How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood). 2006 Jan-Feb; 25(1):248-55. Gellad WF, Huskamp HA, Phillips KA, Haas JS. PMID: 16403761.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    78. Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues. 2006 Jan-Feb; 16(1):4-13. Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. PMID: 16487919.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm. 2005 Dec; 2(12):1294-300. Phillips KA, Ackerman MJ, Sakowski J, Berul CI. PMID: 16360080.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    80. Prescription drug dispensing limits and patterns. Manag Care Interface. 2005 Jul; 18(7):41-6. Phillips KA, Liang SY, Haas JS, Stebbins M, Alldredge BK. PMID: 16060485.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    81. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005 Jun; 4(6):500-9. Phillips KA, Van Bebber SL. PMID: 15915153.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    82. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004 Dec; 5(8):1139-49. Phillips KA, Van Bebber SL. PMID: 15584880.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    83. The effect of area HMO market share on cancer screening. Health Serv Res. 2004 Dec; 39(6 Pt 1):1751-72. Baker LC, Phillips KA, Haas JS, Liang SY, Sonneborn D. PMID: 15533185.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    84. Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control. 2004 Nov; 15(9):883-92. Haggstrom DA, Phillips KA, Liang SY, Haas JS, Tye S, Kerlikowske K. PMID: 15577290.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    85. Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care. 2004 Jul; 42(7):707-14. Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Baker LC, Kaplan CP, Pérez-Stable EJ, Liang SY. PMID: 15213496.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    86. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004 Jul; 10(7 Pt 1):425-32. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. PMID: 15298364.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    87. Are gatekeeper requirements associated with cancer screening utilization? Health Serv Res. 2004 Feb; 39(1):153-78. Phillips KA, Haas JS, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J. PMID: 14965082.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    88. Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res. 2004 Feb; 39(1):179-206. Tye S, Phillips KA, Liang SY, Haas JS. PMID: 14965083.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    89. Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care. 2004 Feb; 10(2 Pt 1):99-107. Liang SY, Phillips KA, Tye S, Haas JS, Sakowski J. PMID: 15011810.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    90. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. J Am Med Womens Assoc (1972). 2004; 59(1):36-42. Phillips KA, Stotland NE, Liang SY, Spetz J, Haas JS, Oren E. PMID: 14768985.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health. 2003 Dec; 93(12):2105-10. Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips KA, Liang SY. PMID: 14652342.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    92. Important step forward in HIV-testing technologies [correction of technolgies]. Am J Prev Med. 2003 Aug; 25(2):167. Phillips KA. PMID: 12880887.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    93. Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey. Am J Prev Med. 2003 May; 24(4):340-8. Phillips KA, Chen JL. PMID: 12726872.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    94. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics. 2003 May; 4(3):231-9. Phillips KA, Veenstra D, Van Bebber S, Sakowski J. PMID: 12718713.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    95. Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care. 2003 May; 41(5):660-8. Haas JS, Phillips KA, Baker LC, Sonneborn D, McCulloch CE. PMID: 12719690.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    96. New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women. J Acquir Immune Defic Syndr. 2003 Feb 01; 32(2):182-91. Phillips KA, Bayer R, Chen JL. PMID: 12571528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    97. Viagra and contraceptives. Health Aff (Millwood). 2003 Jan-Feb; 22(1):277. Phillips KA, Spetz J, Haas JS. PMID: 12528859.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. Measuring what people value: a comparison of "attitude" and "preference" surveys. Health Serv Res. 2002 Dec; 37(6):1659-79. Phillips KA, Johnson FR, Maddala T. PMID: 12546291.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    99. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002 Dec; 37(6):1681-705. Phillips KA, Maddala T, Johnson FR. PMID: 12546292.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    100. Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care. 2002 Sep; 40(9):743-51. Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Liang SY. PMID: 12218765.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    101. Evaluating the potential impact of pharmacogenomics on ADRs. J Manag Care Pharm. 2002 Jul-Aug; 8(4):285-90. Oren E, McCart G, Phillips KA. PMID: 14613422.
      View in: PubMed   Mentions:    Fields:    
    102. Impact of the U.S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002 Feb; 22(2):98-105. Phillips KA, Chen JL. PMID: 11818178.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Kathryn's Networks
    Concepts (273)
    Derived automatically from this person's publications.
    _
    Co-Authors (28)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _